F2G Ltd Announces the Appointment of Michael R. Hodges, M.D. to the Board of Directors

14-Sep-2010 - United Kingdom

F2G Limited announced the appointment of Dr Michael R. Hodges to the Company’s Board of Directors.

Michael R Hodges, M.D., BSc., MRCP (UK) has 20 years of biopharmaceutical development experience and has worked in both biotechnology and large pharmaceutical companies. Whilst at Pfizer Inc. Dr. Hodges was the development team leader for Vfend™, as well as working on the Eraxis™ and Diflucan™ antifungal programs. In addition Dr. Hodges worked on the Zithromax™ and HIV portfolio development programs.

Prior to joining industry at Pfizer Inc. in 1990, Dr. Hodges practiced internal medicine in London, UK. 1989-90 he held an appointment through the Medical Research Council (UK), at St Thomas’ Hospital, London, HIV clinical trials unit. From 1992 to 2001 he held honoree positions with East Kent Hospitals University NHS Foundation Trust.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances